Drug approvalEMAYesterday
The European Medicines Agency approved eight new medicines in May 2026. The article mentions a few specific drugs, including Jascayd (nerandomilast) and Boey (trenibotulinumtoxinE), though details about what diseases they treat are incomplete in this announcement.
WHY IT MATTERSIf you have a rare disease, one of these eight newly approved medicines might be a treatment option available in Europe — check with your doctor to see if any match your condition.
Drug approvalEMAMay 11
The European Medicines Agency's committee met in April 2026 and recommended five new medicines for approval in Europe. One of these medicines is called Cenrifki (tolebrutinib), though the article doesn't provide complete details about what diseases these medicines treat. This is a routine announcement about medicines moving forward in the approval process.
WHY IT MATTERSIf you or a loved one has a condition treated by one of these five newly recommended medicines, approval in Europe may mean the drug becomes available sooner in your country, though availability timelines vary by nation.
PolicyCONGRESSMay 1
Researchers presented new guidelines on how European Union countries and the United Kingdom decide whether to approve and pay for treatments for rare diseases and children's conditions. These guidelines help governments figure out if new medicines are worth the cost and provide good value for patients. The study looked at how different countries make these decisions and what factors they consider most important.
WHY IT MATTERSIf you have a rare disease or care for a child with one in Europe or the UK, these guidelines directly affect which new treatments your doctor can prescribe and whether your insurance will cover them.
ResearchPUBMEDMay 1
Scientists are testing a new way to run drug trials for rare diseases where there aren't enough patients. Instead of only comparing patients at one specific time point, this method allows researchers to use patient information from multiple different dates. This could make it easier and faster to test new medicines for rare diseases without needing as many people in the study.
WHY IT MATTERSIf this method gets adopted by regulators, it could speed up approval timelines for rare disease treatments by allowing researchers to use more real-world patient data, potentially bringing new therapies to patients years sooner.
ResearchPUBMEDApr 30
The UK created a large database called RaDaR to collect detailed health information from patients with rare kidney diseases. With over 37,000 patients enrolled, this database helps researchers understand these diseases better, find new treatments, and run clinical trials more effectively. By gathering this information in one place, scientists can develop new medicines faster for conditions that affect relatively few people.
WHY IT MATTERSIf you have a rare kidney disease, RaDaR's data is helping researchers design better clinical trials and identify which patients might benefit from new treatments — meaning faster access to potential therapies tailored to your specific condition.